uniQure Announces Proposed Public Offering
October 23 2017 - 3:09PM
YASTEST
LEXINGTON, Mass. and AMSTERDAM, the Netherlands,
Oct. 23, 2017 (GLOBE NEWSWIRE) -- uniQure
N.V. (NASDAQ:QURE), a leading gene therapy company advancing
transformative therapies for patients with severe unmet medical
needs, such as hemophilia B, Huntington's disease and congestive
heart failure, today announced that it has commenced an
underwritten public offering of 5,000,000 of its ordinary shares.
All ordinary shares to be sold in the offering will be offered by
uniQure. In addition, uniQure intends to grant the underwriters a
30-day option to purchase up to 750,000 additional ordinary shares
at the public offering price, less underwriting discounts and
commissions. The offering is subject to market and other
conditions, and there can be no assurance as to whether or when the
offering may be completed, or as to the actual size or terms of the
offering.
Leerink Partners and Evercore ISI are acting as
joint book-running managers for the offering. Chardan is acting as
lead manager for the offering.
The securities described above are being offered
by uniQure pursuant to its shelf registration statement on Form S-3
(File No. 333-216701) filed with the Securities Exchange Commission
(the "SEC") on March 15, 2017, as amended on May 15, 2017 and
declared effective by the SEC on May 26, 2017. A preliminary
prospectus supplement and accompanying prospectus relating to the
offering will be filed with the SEC and will be available for free
on the SEC's website at http://www.sec.gov. When available,
copies of the preliminary prospectus supplement and the
accompanying prospectus relating to the offering may be obtained
from Leerink Partners LLC, Attention: Syndicate Department, One
Federal Street, 37th Floor, Boston, MA 02110, by telephone at (800)
808-7525 ext. 6132 or by email at Syndicate@Leerink.com; and
Evercore Group L.L.C., Attention: Equity Capital Markets, 55 East
52nd Street, 36th Floor, New York, NY 10055, or by telephone at
(888) 474-0200, or by email
at ecm.prospectus@evercore.com.
This press release shall not constitute an offer
to sell or the solicitation of an offer to buy these securities,
nor shall there be any sale of these securities, in any state or
other jurisdiction in which such offer, solicitation or sale would
be unlawful prior to registration or qualification under the
securities laws of any such state or other jurisdiction. Any offer,
if at all, will be made only by means of the prospectus supplement
and accompanying prospectus forming a part of the effective
registration statement.
About uniQure
uniQure is delivering on the promise of gene
therapy - single treatments with potentially curative results. We
are leveraging our modular and validated gene therapy technology
platform to advance a pipeline of proprietary and partnered gene
therapies to treat patients with hemophilia, Huntington's disease
and cardiovascular diseases.
Forward-Looking Statement
This press release contains
certain statements that are forward-looking within the meaning of
Section 27a of the Securities Act of 1933, as amended, and that
involve risks and uncertainties. These statements include, without
limitation, statements regarding our anticipated offering and other
statements including the words "may," "will","intend," and similar
expressions (as well as other words or expressions referencing
future events, conditions or circumstances), which constitute and
are intended to identify forward-looking statements. Actual
results may differ materially from those indicated by such
forward-looking statements as a result of various important
factors, including: the uncertainties related to market conditions
and the completion of the public offering on the anticipated terms,
or at all, continued interest in our rare disease portfolio, the
ability to develop our product candidates and technologies, the
impact of changes in the financial markets and global economic
conditions, and other risks as are set forth in uniQure's
Annual Report on Form 10-K and other reports filed by uniQure with
the SEC. uniQure undertakes no obligations to make any revisions to
the forward-looking statements contained in this release or to
update them to reflect events or circumstances occurring after the
date of this release, whether as a result of new information,
future developments or otherwise.
uniQure Contacts
For Investors:
Maria
Cantor
Direct : +339-970-7536
Mobile: 617-680-9452
m.cantor@uniQure.com
Eva M.
Mulder
Direct: +31 20 240
6103
Mobile: +31 6 52 33 15 70
e.mulder@uniQure.com
For Media:
Tom Malone
Direct: 339-970-7758
Mobile: 339-223-8541
t.malone@uniqure.com
This
announcement is distributed by Nasdaq Corporate Solutions on behalf
of Nasdaq Corporate Solutions clients.
The issuer of this announcement warrants that they are solely
responsible for the content, accuracy and originality of the
information contained therein.
Source: uniQure N.V. via Globenewswire
uniQure NV (NASDAQ:QURE)
Historical Stock Chart
From Aug 2024 to Sep 2024
uniQure NV (NASDAQ:QURE)
Historical Stock Chart
From Sep 2023 to Sep 2024